Pembrolizumab-induced myasthenia gravis with isolated diaphragmatic involvement in a lung cancer patient: a case report.

ABSTRACT: Immune-related neuromuscular disorders are rare and potentially life-threatening adverse events of immune checkpoint inhibitors (ICIs) used in the treatment of cancer. They tend to have a chronic course that usually leads to the permanent discontinuation of immunotherapy. We present a case of pembrolizumab-induced myasthenia gravis that only involved the diaphragm. The patient is a 71-year-old female with a history of stage IV lung adenocarcinoma under maintenance therapy with pemetrexed and pembrolizumab after a complete response to first-line chemo-immunotherapy. She complained of orthopnea since the previous month and was admitted due to hypoxemic respiratory failure. Radiology showed decreased lung volumes and atelectatic areas in both lower lung fields. A subsequent bronchoscopy ruled

SUBMITTER: Mouratidou N 

PROVIDER: S-EPMC11866388 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature